Polypragmasy: A clinical pharmacologist’s view


Cite item

Full Text

Abstract

In the modern world, there is a rapid advance in the design and clinical introduction of a huge number of drugs that are able to cure a patient or to improve his/her health status on the one hand and to cause significant harm to his/her health on the other. Polypragmasy is the desire to enhance the efficiency of treatment and to help the patient recover from all developed diseases inevitably leads to the use of a large number of medications. At the present time, polypragmasy as a result of iatrogenia is a serious public health problem, as it is clinically manifested by a reduction in the effectiveness of pharmacotherapy, by the development of severe adverse drug reactions, and by a considerable increase in healthcare expenditures. The reason for the simultaneous prescription of multiple drugs may be comorbidity (multimorbidity), the availability of drugs, as well as clinical guidelines, manuals of professional medical associations, treatment standards that contain recommendations for using combination therapy with more than 5 drugs for only one disease in some cases, the efficiency of which corresponds to a high level of evidence. Currently, the fight against polypragmasy is one of the important tasks in rendering medical care to elderly and senile patients since it is a major risk factor of adverse drug reactions in this category of people. To minimize polypragmasy in elderly patients, it is necessary to use current methods for analyzing each prescription of a drug (the index of rational drug prescribing; an anticholinergic burden scale) and those for optimizing pharmacotherapy with the use of restrictive lists (Beers criteria, STOPP/START criteria) that will be able to reduce the number of errors in the administration of drugs and to maximize the efficiency and safety of pharmacotherapy.

References

  1. Gnjidic D, Hilmer S, Blyth F, Naganathan V, Waite L, Seibel M, McLachlan A, Cumming R, Handelsman D, Le Couteur D. (2012). Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989-995. doi: 10.1016/j.jclinepi.2012.02.018
  2. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383-389. doi: 10.2147/CIA.S2468
  3. Jyrkkä J, Enlund H, Korhonen M, Sulkava R, Hartikainen S. Polypharmacy Status as an Indicator of Mortality in an Elderly Population. Drugs & Aging. 2009;26(12):1039-1048. doi: 10.2165/11319530-000000000-00000
  4. Swine C. Epidemiology of polypharmacy. EAMAVII 3-rd session, January 2008.
  5. Приказ Минздрава России от 2 ноября 2012 г. №575н Об утверждении порядка оказания медицинской помощи по профилю «клиническая фармакология». Доступно по: http://www.rosminzdrav.ru/documents/5534-prikaz-minzdrava-rossii-ot-2-noyabrya-2012-g-575n
  6. Приказ Минздрава России от 20 декабря 2012 г. №1175н «Об утверждении порядка назначения и выписывания лекарственных препаратов, а также форм рецептурных бланков на лекарственные препараты, порядка оформления указанных бланков, их учета и хранения» Доступно по: http://www.rosminzdrav.ru/news/2013/07/02/1607-prikazom-minzdrava-rossii-utverzhden-poryadok-naznacheniya-i-vypisyvaniya-lekarstvennyh-preparatov-formy-retsepturnyh-blankov-a-takzhe-poryadok-ih-oformleniya-ucheta-i-hraneniya
  7. Приказ Минздрава России от 22 января 2014 г. №36н «Об утверждении примерных дополнительных профессиональных программ медицинского образования по специальности «Гериатрия» Доступно по: http://www.consultant.ru/document/cons_doc_LAW_164316/
  8. Payne R, Avery A, Duerden M, Saunders C, Simpson C, Abel G. (2014). Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575-581. doi: 10.1007/s00228-013-1639-9
  9. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995—2010. BMC Med. 2015;13:74. doi: 10.1186/s12916-015-0322-7
  10. Wright R, Sloane R, Pieper C, Ruby-Scelsi C, Twersky J, Schmader K, Hanlon J. (2009). Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: Results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271-280. doi: 10.1016/j.amjopharm.2009.11.002
  11. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83-94. doi: 10.1517/14740338.2012.631910
  12. Astrand B. Avoiding drug-drug interactions. Chemotherapy. 2009;55(4):215-220. doi: 10.1159/000218100
  13. Onder G, Petrovic M, Tangiisuran B, Meinardi M, Markito-Notenboom W, Somers A, Rajkumar C, Bernabei R, van der Cammen T. Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older. Arch Int Med. 2010;170(13):1142-1148. doi: 10.1001/archinternmed.2010.153
  14. Лазебник Л.Б., Вeрткин А.Л., Конев Ю.В., Ли Е. Д, Скотников А.С. Старение: профессиональный врачебный подход. Москва: Эксмо; 2014.
  15. Walckiers D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Arch Public Health. 2015;73:50. doi: 10.1186/s13690-015-0095-7
  16. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy — an individual-based study of the Swedish population 2005—2008. BMC Clin Pharmacol. 20102;10:16. doi: 10.1186/1472-6904-10-16
  17. Elliott R, Lee CY. Anticholinergic load and adverse outcomes in older people. Australian Pharmacist. 2009;28(11):970-975.
  18. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165. doi: 10.1002/14651858.CD008165.pub3
  19. Naples J, Marcum Z, Perera S, Gray S, Newman A, Simonsick E, Yaffe K, Shorr R, Hanlon J. Concordance Between Anticholinergic Burden Scales. J Am Geriatr Soc. 2015;63(10):2120-2124. doi: 10.1111/jgs.13647
  20. Ancelin M. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-459.
  21. Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317-1324. doi: 10.1001/archinternmed.2009.229
  22. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-1486. doi: 10.1177/0091270006292126
  23. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099-1105. doi: 10.1001/archinte.161.8.1099
  24. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9(6):430-434.
  25. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-2246. doi: 10.1111/jgs.13702
  26. Сычев Д.А., Данилина К.С., Головина О.В. Частота назначения потенциально не рекомендованных препаратов (по критериям Бирса) пожилым пациентам, находящимся в терапевтических отделениях многопрофильного стационара Терапевтический архив. 2015;87(1):27-30.
  27. O’Mahony D, O’Sullivan D, Byrne S, O’Connor M, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and Ageing. 2014;44(2):213-218. doi: 10.1093/ageing/afu145
  28. Данилина К.С., Сычев Д.А., Головина О.В., Ильина Е.С., Горботенкова С.В. Частота назначения потенциально не рекомендованных лекарственных препаратов (по критериям «STOPP START») пожилым пациентам, находящимся в терапевтических отделениях стационара: результаты фармакоэпидемиологического исследования. Фарматека. 2015;13(306):25-28.
  29. Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845-854. doi: 10.1038/clpt.2011.44

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies